Literature DB >> 9521105

Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant.

L Hong1, J A Hartsuck, S Foundling, J Ermolieff, J Tang.   

Abstract

The mutation Ala28 to serine in human immunodeficiency virus, type 1, (HIV-1) protease introduces putative hydrogen bonds to each active-site carboxyl group. These hydrogen bonds are ubiquitous in pepsin-like eukaryotic aspartic proteases. In order to understand the significance of this difference between HIV-1 protease and homologous, eukaryotic aspartic proteases, we solved the three-dimensional structure of A28S mutant HIV-1 protease in complex with a peptidic inhibitor U-89360E. The structure has been determined to 2.0 A resolution with an R factor of 0.194. Comparison of the mutant enzyme structure with that of the wild-type HIV-1 protease bound to the same inhibitor (Hong L, Treharne A, Hartsuck JA, Foundling S, Tang J, 1996, Biochemistry 35:10627-10633) revealed double occupancy for the Ser28 hydroxyl group, which forms a hydrogen bond either to one of the oxygen atoms of the active-site carboxyl or to the carbonyl oxygen of Asp30. We also observed marked changes in orientation of the Asp25 catalytic carboxyl groups, presumably caused by the new hydrogen bonds. These observations suggest that catalytic aspartyl groups of HIV-1 protease have significant conformational flexibility unseen in eukaryotic aspartic proteases. This difference may provide an explanation for some unique catalytic properties of HIV-1 protease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521105      PMCID: PMC2143907          DOI: 10.1002/pro.5560070209

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  20 in total

1.  pH dependence of kinetic parameters of pepsin, rhizopuspepsin, and their active-site hydrogen bond mutants.

Authors:  Y Lin; M Fusek; X Lin; J A Hartsuck; F J Kezdy; J Tang
Journal:  J Biol Chem       Date:  1992-09-15       Impact factor: 5.157

2.  Cleavage of the X-Pro peptide bond by pepsin is specific for the trans isomer.

Authors:  J E Vance; D A LeBlanc; R E London
Journal:  Biochemistry       Date:  1997-10-28       Impact factor: 3.162

3.  Domain flexibility in aspartic proteinases.

Authors:  A Sali; B Veerapandian; J B Cooper; D S Moss; T Hofmann; T L Blundell
Journal:  Proteins       Date:  1992-02

4.  Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.

Authors:  J Ermolieff; X Lin; J Tang
Journal:  Biochemistry       Date:  1997-10-07       Impact factor: 3.162

5.  Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases.

Authors:  L Hong; A Treharne; J A Hartsuck; S Foundling; J Tang
Journal:  Biochemistry       Date:  1996-08-20       Impact factor: 3.162

Review 6.  Structure-based inhibitors of HIV-1 protease.

Authors:  A Wlodawer; J W Erickson
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

7.  Crystal structure of human pepsin and its complex with pepstatin.

Authors:  M Fujinaga; M M Chernaia; N I Tarasova; S C Mosimann; M N James
Journal:  Protein Sci       Date:  1995-05       Impact factor: 6.725

8.  Structure and refinement at 1.8 A resolution of the aspartic proteinase from Rhizopus chinensis.

Authors:  K Suguna; R R Bott; E A Padlan; E Subramanian; S Sheriff; G H Cohen; D R Davies
Journal:  J Mol Biol       Date:  1987-08-20       Impact factor: 5.469

9.  Inhibition and catalytic mechanism of HIV-1 aspartic protease.

Authors:  A M Silva; R E Cachau; H L Sham; J W Erickson
Journal:  J Mol Biol       Date:  1996-01-19       Impact factor: 5.469

10.  Human immunodeficiency virus, type 1 protease substrate specificity is limited by interactions between substrate amino acids bound in adjacent enzyme subsites.

Authors:  T W Ridky; C E Cameron; J Cameron; J Leis; T Copeland; A Wlodawer; I T Weber; R W Harrison
Journal:  J Biol Chem       Date:  1996-03-01       Impact factor: 5.157

View more
  10 in total

1.  Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.

Authors:  Nancy M King; Laurence Melnick; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Shiow-Shong Yang; Yun Gao; Xiaoyi Nie; Charles Zepp; Donald L Heefner; Celia A Schiffer
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

2.  Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Authors:  Yu-Chung E Chang; XiaXia Yu; Ying Zhang; Yunfeng Tie; Yuan-Fang Wang; Sofiya Yashchuk; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

3.  In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.

Authors:  P J Yates; R Hazen; M St Clair; L Boone; M Tisdale; R C Elston
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

4.  Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.

Authors:  Yasuhiro Koh; Manabu Aoki; Matthew L Danish; Hiromi Aoki-Ogata; Masayuki Amano; Debananda Das; Robert W Shafer; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

Review 5.  Receptor-ligand molecular docking.

Authors:  Isabella A Guedes; Camila S de Magalhães; Laurent E Dardenne
Journal:  Biophys Rev       Date:  2013-12-21

6.  A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.

Authors:  Masayuki Amano; Yasuhiro Koh; Debananda Das; Jianfeng Li; Sofiya Leschenko; Yuan-Fang Wang; Peter I Boross; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

7.  A novel HIV-1 protease inhibitor, GRL-044, has potent activity against various HIV-1s with an extremely high genetic barrier to the emergence of HIV-1 drug resistance.

Authors:  Manabu Aoki; Simon B Chang; Debananda Das; Cuthbert Martyr; Nicole S Delino; Yuki Takamatsu; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Glob Health Med       Date:  2019-10-31

8.  Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance.

Authors:  Yuki Takamatsu; Manabu Aoki; Haydar Bulut; Debananda Das; Masayuki Amano; Venkata Reddy Sheri; Ladislau C Kovari; Hironori Hayashi; Nicole S Delino; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

9.  A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

Authors:  Kazuhisa Yoshimura; Ryohei Kato; Mark F Kavlick; Aline Nguyen; Victor Maroun; Kenji Maeda; Khaja A Hussain; Arun K Ghosh; Sergei V Gulnik; John W Erickson; Hiroaki Mitsuya
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

10.  Related Endogenous Retrovirus-K Elements Harbor Distinct Protease Active Site Motifs.

Authors:  Matthew G Turnbull; Renée N Douville
Journal:  Front Microbiol       Date:  2018-07-18       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.